Rx Minute: Biopharmaceutical companies embracing personalized medicine

A new report from the Tufts Center for the Study of Drug Development finds that biopharmaceutical companies are committed to researching and developing personalized medicines. The data show, for the first time, the extent to which companies are embracing this new research: of the companies surveyed, 94% said they are investing in personalized medicine (PM) research. In many instances, companies’ investment is translating into the development of therapies that have a companion diagnostic.

Greetings from the PhRMA Annual Meeting

04.12.13 | By

The past few days have been an excellent reminder of the accomplishments of our organization during the past year under the leadership of Dr. John Lechleiter. We have made important progress in our ongoing mission to protect and expand medical innovation and provide patients with access to disease-altering new therapies.

Restoring Hope: Empowering Patients to Break Through Their Pain

It’s obvious at #PhRMA13 that providing patients with the treatments they need is at the forefront of everyone’s mind. To determine what treatments are needed, patient engagement is becoming increasingly important. The American Osteopathic Association is launching its “Break Through Your Pain” campaign next week to restore hope for patients suffering from chronic pain and encouraging them to get actively engaged in their health.

Disruption in Digital Health Innovation, and Why It's a Good Thing

04.11.13 | By

The third and final panel today at #PhRMA13 tried on a new definition of what we consider "disruptive", and why we should like it.  A disruptive technology or innovation improves not just what is known, but changes the modus operandi in completely unforeseen ways. Cloud computers, digital photography, downloadable music, mass-produced cars; these technologies didn't improve upon a specific line of thought, they renovated what had been considered possible.

Rx Minute: Cancer Drug Abandonment and Early HIV Treatment

This month's edition of Rx Minute focuses on two major new studies. First, we highlight a new study in the Journal of Oncology Practice and the American Journal of Managed Care which found a surprisingly high rate of abandonment of oral anti-cancer drugs, with high cost-sharing as a key driving factor. Second, we recap a new study sponsored by the National Institute of Allergy and Infectious Disease that produced strong evidence that antiretroviral treatments can prevent HIV/AIDS transmissions. 
Cancer Drug Abandonment Common

Rx Minute: Adherence to Medicines Reduces Overall Health Care Costs

A new study published in Health Affairs finds that for patients with congestive heart failure, hypertension, diabetes, or dyslipidemia (lipid disorders including high cholesterol), adherence to medicines leads to lower total health care cost. While many studies have shown an association between taking medicines as prescribed and lower costs, this study uses a more robust methodology to mathematically account for other variables at play.

Disruptive Innovation and the Future of the Drug Lifecycle

I’m at the PhRMA 2013 Annual Meeting in San Diego, where a panel is discussing disruptive innovation and the new challenges and opportunities it opens for the biopharmaceutical industry.

It’s a great topic. 

#PhRMA13 Morning Panelists Off To a Rollicking Start

04.11.13 | By

The morning panels of PhRMA's Annual Meeting provided a welcome blast of new thinking on how to create a positive geography for innovation, and further how that science gets done. As an added bonus, California Lieutenant Governor Gavin Newsom gave a super-charged address explaining how a state in grave economic flux plans to keep their leadership in bioscience.

Disruptive Innovation: Success Breeds Longevity

Disruptive innovations in health care are often the drivers of new technologies and new treatments that enhance and build upon old modalities. The birth of osteopathic medicine in the 1870s can be seen as a “disruptive innovation” in its revolutionary approach to medical treatment.

Castellani: A Long-term Vision for Innovative Biopharmaceutical Research Sector Needed

04.11.13 | By

John Castellani, PhRMA’s president & CEO, opened today’s afternoon session of PhRMA’s Annual Meeting in San Diego in a speech calling on policymakers, healthcare stakeholders, biopharmaceutical industry critics and sector allies alike to recognize and leverage the value of innovative medicines.


Subscribe to RSS - Opinion